Compare · ABC vs COSM
ABC vs COSM
Side-by-side comparison of AmerisourceBergen Corporation (ABC) and Cosmos Health Inc. (COSM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABC and COSM operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- ABC is the larger of the two at $28.47B, about 841.1x COSM ($33.9M).
- COSM has hit the wire 7 times in the past 4 weeks while ABC has been quiet.
- ABC has more recent analyst coverage (17 ratings vs 0 for COSM).
- Company
- AmerisourceBergen Corporation
- Cosmos Health Inc.
- Price
- -
- -
- Market cap
- $28.47B
- $33.9M
- 1M return
- -
- +11.40%
- 1Y return
- -
- -98.42%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 0
- 7
- Recent ratings
- 17
- 0
AmerisourceBergen Corporation
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; offers specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets, as well as provides demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Conshohocken, Pennsylvania.
Cosmos Health Inc.
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.
Latest ABC
- Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
- Clark Gina sold $253,528 worth of shares (1,100 units at $230.48), decreasing direct ownership by 4% to 24,802 units (SEC Form 4)
- SEC Form SC 13G filed by AmerisourceBergen Corporation
- SEC Form SC 13G/A filed by AmerisourceBergen Corporation (Amendment)
- AmerisourceBergen Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- AmerisourceBergen Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- SEC Form FWP filed by AmerisourceBergen Corporation
- Nally Dennis M was granted 132 shares, increasing direct ownership by 1% to 9,383 units (SEC Form 4)
- Baumann Werner was granted 106 shares, increasing direct ownership by 17% to 720 units (SEC Form 4)
- Tyler Lauren M was granted 106 shares, increasing direct ownership by 17% to 720 units (SEC Form 4)
Latest COSM
- Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription
- Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days
- SEC Form 8-K filed by Cosmos Health Inc.
- Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
- Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion
- Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue
- Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline
- Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
- Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market
- Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units